



**SUSANA VALLEJO FERNÁN**

Generated from: Editor CVN de FECYT

Date of document: 18/01/2019

**v 1.4.0**

8259b974d86b58619eae46b601b869bd

This electronic file (PDF) has embedded CVN technology (CVN-XML). The CVN technology of this file allows you to export and import curricular data from and to any compatible data base. List of adapted databases available at: <http://cvn.fecyt.es/>



## Summary of CV

This section describes briefly a summary of your career in science, academic and research; the main scientific and technological achievements and goals in your line of research in the medium -and long- term. It also includes other important aspects or peculiarities.

### PREDOCTORAL PERIOD

In 1996, I obtained by BSc in Biology at Universidad Complutense de Madrid. I then started my pre-doctoral training at Unidad de Investigación, Hospital Universitario de Getafe (HUG) under the supervision of Dr. Leocadio Rodríguez Mañas. Since my incorporation I participated in the following main research lines focused on vascular pathophysiology in diabetes mellitus and human ageing. During my predoctoral training, I was funded by a fellowship associated to the research project "Glicosilación no enzimática de proteínas, stress oxidativo y expresión de las sintasas del óxido nítrico en la disfunción endotelial asociada al envejecimiento" (FIS 99/0246). In 2000, I defended my Doctoral Thesis entitled: "Mechanisms of endothelial dysfunction in diabetes mellitus", under the co-direction of Dr. Leocadio Rodríguez Mañas and Prof. Carlos F. Sánchez Ferrer, Catedrático de Farmacología at Facultad de Medicina, Universidad Autónoma de Madrid (UAM) obtaining the qualification "Sobresaliente Cum Laude". The research work performed during my predoctoral training yielded 9 international publications in JCR indexed journals, including Diabetologia or Br J Pharmacol, among other, included in the first quartile of their respective subject category.

### POSTDOCTORAL PERIOD

As I PhD, I continued my research tasks in Dr Rodríguez-Mañas group at Unidad de Investigación ( HUG) for almost 9 years, to deepen into the mechanisms underlying diabetic vasculopathy, but also to explore the alterations occurring during healthy human ageing. During my postdoctoral period, I was initially funded by a grant-associated fellowship "Actividad de diferentes agentes farmacológicos sobre la disfunción endotelial del envejecimiento mediada por estrés oxidativo" (2002-2004), followed by a research contract linked to the research project "Actividad de diferentes agentes farmacológicos sobre la disfunción endotelial del envejecimiento mediada por estrés oxidativo" (2005-2006), Comunidad de Madrid. I then obtained a "Contrato de Apoyo a la Investigación en el Sistema Nacional de Salud" (2007-2009) funded by Instituto de Salud Carlos III, FIS.

Since January 2010, I have joined the research group FARMAVASM headed by Prof. Sánchez-Ferrer ([www.uam.es/farmavas](http://www.uam.es/farmavas)). As a Contracted Investigator associated to the projects: "Adipoquinas: ¿nexo de unión entre obesidad, resistencia a insulina e inflamación vascular? Papel de resistina, visfatina y apelina". Ministerio de Ciencia e Innovación (SAF2008-01291), 2009-2011, led by Dr. Concepción Peiró (UAM) in collaboration with Dr. Raffaele Carraro (Hospital Universitario de La Princesa). "Papel de la adipoquina visfatina como promotor y biomarcador de daño vascular asociado a enfermedades metabólicas"(2012-2014). Ministerio de Ciencia e Innovación. SAF2011-28011 led by Dra Concepción Peiró. "Adipoquinas y envejecimiento vascular. Mecanismos implicados y modulación farmacológica". Ministerio de Economía y Competitividad (SAF2014-52762-R) led by: Dra Concepción Peiró y Dr. C.F. Sánchez Ferrer. In actuality, " Adipoquina: nuevas dianas farmacológicas para prevenir el envejecimiento vascular". SAF2017-84776-R. Co-IPs: Concepción Peiró/CarlosF. Sánchez Ferrer. Ministerio de Economía y Competitividad, Plan Nacional de I+D+i, 2018-2020.



CURRÍCULUM VÍTAE NORMALIZADO

8259b974d86b58619eae46b601b869bd

**SUSANA VALLEJO FERNÁN**

Surname(s): **VALLEJO FERNÁN**  
 Name: **SUSANA**  
 DNI: **51682502F**  
 Date of birth: **23/09/1971**  
 Gender: **Female**  
 Nationality: **Spain**  
 Country of birth: **Spain**  
 Aut. region/reg. of birth: **Community of Madrid**  
 Contact province: **Madrid**  
 City of birth: **MADRID**  
 Contact address: **C/ ALBANIA 6, 4ª**  
 Postcode: **28022**  
 Contact country: **Spain**  
 Contact aut. region/reg.: **Community of Madrid**  
 Contact city: **MADRID**  
 Land line phone: **(0034) 914975411**  
 Email: **susana.vallejo@uam.es**  
 Mobile phone: **(0034) 659472844**

**Current professional situation**

**Employing entity:** Universidad Autónoma de Madrid      **Type of entity:** University

**Department:** Farmacología y Terapéutica, Facultad de Medicina

**Professional category:** Investigador contratado

**Start date:** 01/01/2018

**Type of contract:** Temporary employment contract

**Previous positions and activities**

	<b>Employing entity</b>	<b>Professional category</b>	<b>Start date</b>
<b>1</b>	Universidad Autónoma de Madrid	Investigador contratado	01/01/2015
<b>2</b>	Universidad Autónoma de Madrid	Investigador contratado	01/01/2012
<b>3</b>	Universidad Autónoma de Madrid	Investigador contratado	01/01/2010
<b>4</b>	Instituto de Salud Carlos III	Investigador contratado	01/01/2007
<b>5</b>	Comunidad de Madrid	Investigador contratado	01/01/2005
<b>6</b>	Comunidad de Madrid	Becaria postdoctoral	01/01/2002
<b>7</b>	Instituto de Salud Carlos III	Becaria predoctoral	01/01/1999

**1** **Employing entity:** Universidad Autónoma de Madrid

**Professional category:** Investigador contratado

**Start-End date:** 01/01/2015 - 2017

**Duration:** 3 years



- |  |   |
|--|---|
| <p><b>2</b> <b>Employing entity:</b> Universidad Autónoma de Madrid<br/><b>Professional category:</b> Investigador contratado<br/><b>Start-End date:</b> 01/01/2012 - 31/12/2014</p> | <p><b>Type of entity:</b> University<br/><b>Duration:</b> 3 years</p>           |
| <p><b>3</b> <b>Employing entity:</b> Universidad Autónoma de Madrid<br/><b>Professional category:</b> Investigador contratado<br/><b>Start-End date:</b> 01/01/2010 - 31/12/2011</p> | <p><b>Type of entity:</b> University<br/><b>Duration:</b> 2 years</p>           |
| <p><b>4</b> <b>Employing entity:</b> Instituto de Salud Carlos III<br/><b>Professional category:</b> Investigador contratado<br/><b>Start-End date:</b> 01/01/2007 - 31/12/2009</p>  | <p><b>Type of entity:</b> Public Research Body<br/><b>Duration:</b> 3 years</p> |
| <p><b>5</b> <b>Employing entity:</b> Comunidad de Madrid<br/><b>Professional category:</b> Investigador contratado<br/><b>Start-End date:</b> 01/01/2005 - 31/12/2006</p>            | <p><b>Type of entity:</b> Hospital<br/><b>Duration:</b> 2 years</p>             |
| <p><b>6</b> <b>Employing entity:</b> Comunidad de Madrid<br/><b>Professional category:</b> Becaria postdoctoral<br/><b>Start-End date:</b> 01/01/2002 - 31/12/2004</p>               | <p><b>Type of entity:</b> Hospital<br/><b>Duration:</b> 3 years</p>             |
| <p><b>7</b> <b>Employing entity:</b> Instituto de Salud Carlos III<br/><b>Professional category:</b> Becaria predoctoral<br/><b>Start-End date:</b> 01/01/1999 - 31/12/2001</p>      | <p><b>Type of entity:</b> Public Research Body<br/><b>Duration:</b> 2 years</p> |



## Education

### University education

#### 1st and 2nd cycle studies and pre-Bologna degrees

- 1** **University degree:** Higher degree  
**Name of qualification:** LICENCIADO EN CIENCIAS BIOLÓGICAS  
**Degree awarding entity:** UNIVERSIDAD COMPLUTENSE DE MADRID **Type of entity:** University  
**Date of qualification:** 1996
- 2** **University degree:** FP II  
**Name of qualification:** TÉCNICO ESPECIALISTA DE LABORATORIO  
**Degree awarding entity:** IES LAS MUSAS  
**Date of qualification:** 1993

#### Doctorates

**Doctorate programme:** BIOLOGIA  
**Degree awarding entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Date of degree:** 12/2000

#### Specialised, lifelong, technical, professional and refresher training (other than formal academic and healthcare studies)

**Training title:** Curso de Capacitación para manejo de animales de experimentación, Categoría C  
**Awarding entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**End date:** 2015 **Duration in hours:** 42 hours

#### Language skills

Language	Listening skills	Reading skills	Spoken interaction	Speaking skills	Writing skills
English					



## Teaching experience

### General teaching experience

- 1 Name of the course:** Técnicas experimentales de Investigación Farmacológica  
**University degree:** Doctorate course: "Biopatología de la pared vascular: perspectivas actuales e implicaciones terapéuticas".  
**Start date:** 01/06/2009 **End date:** 03/06/2009  
**End date:** 03/06/2009  
**Entity:** Universidad Autónoma de madrid
- 2 Name of the course:** Técnicas experimentales de Investigación Farmacológica  
**University degree:** Doctorate course: "Biopatología de la pared vascular: perspectivas actuales e implicaciones terapéuticas".  
**Start date:** 26/05/2003 **End date:** 28/05/2003  
**End date:** 28/05/2003  
**Entity:** Universidad Autónoma de madrid
- 3 Name of the course:** Experimental Techniques in Pharmacological Research  
**University degree:** University Master: "Pharmacological Research"  
**End date:** 01/2017  
**Entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Faculty, institute or centre:** Facultad de Medicina
- 4 Name of the course:** Técnicas Experimentales en Investigación Farmacológica  
**University degree:** University Master: "Investigación Farmacológica"  
**End date:** 01/2016  
**Entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Faculty, institute or centre:** Facultad de Medicina
- 5 Name of the course:** Técnicas Experimentales en Investigación Farmacológica  
**University degree:** University Master: "Investigación Farmacológica"  
**End date:** 01/2015  
**Entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Faculty, institute or centre:** Facultad de Medicina
- 6 Name of the course:** Técnicas Experimentales en Investigación Farmacológica  
**University degree:** University Master: "Investigación Farmacológica"  
**End date:** 01/2014  
**Entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Faculty, institute or centre:** Facultad de Medicina
- 7 Name of the course:** Técnicas Experimentales en Investigación Farmacológica  
**University degree:** University Master: "Investigación Farmacológica"  
**End date:** 01/2013  
**Entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Faculty, institute or centre:** Facultad de Medicina



- 8 Name of the course:** Técnicas Experimentales en Investigación Farmacológica  
**University degree:** University Master: "Investigación Farmacológica"  
**End date:** 01/2012  
**Entity:** Universidad Autónoma de Madrid **Type of entity:** University  
**Faculty, institute or centre:** Facultad de Medicina

## Scientific and technological experience

### Scientific or technological activities

#### R&D projects funded through competitive calls of public or private entities

- 1 Name of the project:** Adipoquinas: nuevas dianas farmacológicas para prevenir el envejecimiento vascular  
**Entity where project took place:** Facultad de Medicina. Farmacología. UAM **Type of entity:** University Department  
**City of entity:** MADRID, Community of Madrid, Spain  
**Name principal investigator (PI, Co-PI...):** Concepción Peiró Vallejo; Carlos F. Sánchez Ferrer  
**Funding entity or bodies:** Ministerio de Economía y Competitividad **Type of entity:** Ministerio  
**City funding entity:** Madrid, Community of Madrid, Spain  
**Start-End date:** 2018 - 01/01/2020
- 2 Name of the project:** Adipoquinas y envejecimiento vascular. Mecanismos implicados y modulación farmacológica".  
**Entity where project took place:** Facultad de Medicina. Farmacología UAM **Type of entity:** University  
**City of entity:** MADRID, Community of Madrid, Spain  
**Name principal investigator (PI, Co-PI...):** CONCEPCION PEIRO VALLEJO  
**Funding entity or bodies:** Ministerio de Economía y Competitividad **Type of entity:** Public Research Body  
**City funding entity:** MADRID, Community of Madrid, Spain  
**Start-End date:** 2015 - 2017
- 3 Name of the project:** Papel de la adipoquina visfatina como promotor y biomarcador de daño vascular asociado a enfermedades metabólicas  
**Entity where project took place:** Facultad de Medicina. Farmacología UAM  
**City of entity:** MADRID, Community of Madrid, Spain  
**Funding entity or bodies:** Ministerio de Ciencia e Innovación **Type of entity:** Public Research Body  
**City funding entity:** MADRID, Community of Madrid, Spain  
**Start-End date:** 2012 - 2014
- 4 Name of the project:** Adipoquinas: ¿ Nexo de unión entre obesidad, resistencia a insulina e inflamación vascular? Papel de resistina, visfatina y apelina". Ministerio de Ciencia e Innovación (SAF 2008-01291).  
**Entity where project took place:** Facultad de Medicina. Farmacología UAM  
**City of entity:** MADRID, Community of Madrid, Spain





**Start-End date:** 2010 - 2012

**5 Name of the project:** Efecto de los agonistas PPARs sobre el estrés oxidativo y la inflamación asociados a la disfunción endotelial del envejecimiento humano

**Entity where project took place:** Hospital Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** MADRID, Community of Madrid, Spain

**Funding entity or bodies:**

Fundación Investigación Médica Mutua Madrileña. **Type of entity:** Foundation

**City funding entity:** MADRID, Community of Madrid, Spain

**Start-End date:** 2008 - 2010

**Total amount:** 25.000 €

**6 Name of the project:** Impacto de los factores de riesgo cardiovascular y su agregación sobre la disfunción endotelial en ancianos” (PI08/1649)

**Entity where project took place:** Hospital Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** MADRID, Community of Madrid, Spain

**Funding entity or bodies:**

Fondo de Investigación Sanitaria (FIS) del Instituto de **Type of entity:** Public Research Body Salud Carlos III.

**City funding entity:** MADRID, Community of Madrid, Spain

**Start-End date:** 2008 - 2010

**7 Name of the project:** Proyecto integrado en la Red Temática de Investigación Cooperativa Envejecimiento y Fragilidad: RETICEF (RD06/0013).

**Entity where project took place:** Hospital Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** MADRID, Community of Madrid, Spain

**Funding entity or bodies:**

Fondo de Investigación Sanitaria (FIS) del Instituto de **Type of entity:** Public Research Body Salud Carlos III.

**City funding entity:** MADRID, Community of Madrid, Spain

**Start-End date:** 2007 - 2010

**8 Name of the project:** Causas potenciales del estrés oxidativo asociado a la disfunción endotelial del envejecimiento humano. PI 05/2224

**Entity where project took place:** Hospital Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** MADRID, Community of Madrid, Spain

**Funding entity or bodies:**

Fondo de Investigación Sanitaria (FIS) del Instituto de **Type of entity:** Public Research Body Salud Carlos III.

**City funding entity:** MADRID, Community of Madrid, Spain

**Start-End date:** 2006 - 2008

**9 Name of the project:** Factores asociados a la disfunción endotelial de la diabetes en el anciano.PI 04/1955

**Entity where project took place:** Hospital Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** Madrid, Community of Madrid, Spain

**Funding entity or bodies:**

Fondo de Investigación Sanitaria (FIS) del Instituto de **Type of entity:** Public Research Body  
Salud Carlos III.

**City funding entity:** MADRID, Community of Madrid, Spain

**Start-End date:** 2005 - 2007

- 10 Name of the project:** Actividad de diferentes agentes farmacológicos sobre la disfunción endotelial del envejecimiento mediada por estrés oxidativo

**Entity where project took place:** Hospital  
Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** Madrid, Community of Madrid, Spain

**Start-End date:** 2004 - 2005

- 11 Name of the project:** Defectos metabólicos y moleculares de la diabetes mellitus y sus complicaciones: Terapia génica y celular

**Entity where project took place:** Hospital  
Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** Madrid, Community of Madrid, Spain

**Funding entity or bodies:**

Instituto de Salud Carlos III

**Type of entity:** Public Research Body

**City funding entity:** Madrid, Community of Madrid, Spain

**Start-End date:** 2003 - 2004

- 12 Name of the project:** Envejecimiento y diabetes: efecto del estrés oxidativo sobre la pared vascular

**Entity where project took place:** Hospital  
Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** Madrid, Community of Madrid, Spain

**Funding entity or bodies:**

Comunidad de Madrid

**Type of entity:** CAM 08.4/0030/20019

**City funding entity:** Madrid, Community of Madrid, Spain

**Start-End date:** 2002 - 2004

- 13 Name of the project:** Papel del estrés oxidativo y de la inflamación en la disfunción endotelial asociada al envejecimiento

**Entity where project took place:** Hospital  
Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** Madrid, Community of Madrid, Spain

**Funding entity or bodies:**

Fondo de Investigación Sanitaria (FIS) Instituto de  
Salud Carlos III

**Type of entity:** Public Research Body

**Start-End date:** 2002 - 2004

- 14 Name of the project:** Glicosilación no enzimática de proteínas, estrés oxidativo y expresión de las sintasa del óxido nítrico en la disfunción endotelial asociada al envejecimiento" FIS (99/0246)

**Entity where project took place:** Hospital  
Universitario de Getafe

**Type of entity:** Healthcare Institutions

**City of entity:** Madrid, Community of Madrid, Spain

**Start-End date:** 1999 - 2001



## Scientific and technological activities

### Scientific production

#### Publications, scientific and technical documents

- 1** MARTYNA PLENS-GALASKA; MALGORZATA SZELAG; AIDA COLLADO; SUSANA VALLLEJO; MARIELLA RAMOS-GONZALEZ; JOANNA WESOLY; MARIA JESUS SANZ; MARIA JESUS SANZ; CONCEPCION PEIRO; HANS A.R. BLUYSSSEN. Genome-wide inhibition of pro-atherogenic gene expression by multi-STAT targeting compounds as a novel treatment strategy of CVD. *Front. Immunol.* 2018.  
**Format:** Journal
- 2** C. ESPINOSA-DÍEZ; V. MIGUEL; S. VALLEJO; F.J. SANCHEZ; E. SANDOVAL; E. BLANCO; P. CANNATA; C. PEIRÓ; C.F. SÁNCHEZ-FERRER; S. LAMAS. Role of glutathione biosynthesis in endothelial dysfunction and fibrosis. *Redox Biol.* 14, pp. 88 - 99. 2018.  
**Format:** Journal
- 3** Alvaro San Hipólito-Luengo; A Alcaide; M RAMOS-GONZÁLEZ; Elena Cercas; Susana Vallejo; Alejandra Romero; E Talero; C.F. Sánchez-Ferrer; V. Motilva; C. Peiró. Dual Effects of Resveratrol on Cell Death and Proliferation of Colon Cancer Cells. *Nutr Cancer.* 69 - 7, pp. 1019 - 1027. 2017.  
**Format:** Journal
- 4** Agua Sobrino; Susana Vallejo; Susana Novella; Macarena Lázaro Franco; Ana Mompeón; Carlos Bueno Betí; Thomas Walther; Carlos Sánchez Ferrer; Concepción Peiró; Carlos Hermenegildo. Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation. *Biochemical pharmacology.* 129, pp. 67 - 72. 2017. ISSN 1873-2968
- 5** Tania Romacho; Susana Vallejo; Laura A Villalobos; Nina Wronkowitz; Ira Indrakusuma; Henrike Sell; Jüergen Eckel; Carlos F Sánchez Ferrer; Concepción Peiró. Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release. *Journal of hypertension.* 34 - 5, pp. 869 - 876. 2016. ISSN 1473-5598
- 6** Laura A Villalobos; Álvaro San Hipólito Luengo; Mariella Ramos González; Elena Cercas; Susana Vallejo; Alejandra Romero; Tania Romacho; Raffaele Carraro; Carlos F Sánchez Ferrer; Concepción Peiró. The Angiotensin-(1-7)/Mas Axis Counteracts Angiotensin II-Dependent and -Independent Pro-inflammatory Signaling in Human Vascular Smooth Muscle Cells. *Frontiers in pharmacology.* 7, pp. 482. (Switzerland): 2016. ISSN 1663-9812
- 7** Amie J Moyes; Rayomand S Khambata; Inmaculada Villar; Kristen J Bubb; Reshma S Baliga; Natalie G Lumsden; Fang Xiao; Paul J Gane; Anne-Sophie Rebstock; Roberta J Worthington; Michela I Simone; Filipa Mota; Fernando Rivilla; Susana Vallejo; Concepción Peiró; Carlos F Sánchez Ferrer; Snezana Djordjevic; Mark J Caulfield; Raymond J MacAllister; David L Selwood; Amrita Ahluwalia; Adrian J Hobbs. Endothelial C-type natriuretic peptide maintains vascular homeostasis. *The Journal of clinical investigation.* 124 - 9, pp. 4039 - 4051. 2014. ISSN 1558-8238
- 8** Diana González Peña; Javier Angulo; Susana Vallejo; Clara Colina Coca; Begoña de Ancos; Carlos F Sánchez Ferrer; Concepción Peiró; Concepción Sánchez Moreno. High-cholesterol diet enriched with onion affects endothelium-dependent relaxation and NADPH oxidase activity in mesenteric microvessels from Wistar rats. *Nutrition & metabolism.* 11, pp. 57. 2014. ISSN 1743-7075



- 9** Susana Vallejo; Erika Palacios; Tania Romacho; Laura Villalobos; Concepción Peiró; Carlos F Sánchez Ferrer. The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. *Cardiovascular diabetology*. 13, pp. 158. 2014. ISSN 1475-2840
- 10** Concepción Peiró; Susana Vallejo; Florian Gembardt; Erika Palacios; Susana Novella; Verónica Azcutia; Leocadio Rodríguez Mañas; Carlos Hermenegildo; Carlos F Sánchez Ferrer; Thomas Walther. Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. *The Journal of physiology*. 591 - 9, pp. 2275 - 2285. 2013. ISSN 1469-7793
- 11** Javier Angulo; Susana Vallejo; Mariam El Assar; Javier García Septiem; Carlos F Sánchez Ferrer; Leocadio Rodríguez Mañas. Age-related differences in the effects of  $\alpha$  and  $\gamma$  peroxisome proliferator-activated receptor subtype agonists on endothelial vasodilation in human microvessels. *Experimental gerontology*. 47 - 9, pp. 734 - 740. 2012. ISSN 1873-6815
- 12** Fernando Rivilla; Susana Vallejo; Concepción Peiró; Carlos F Sánchez Ferrer. Characterization of endothelium-dependent relaxations in the mesenteric vasculature: a comparative study with potential pathophysiological relevance. *Journal of pediatric surgery*. 47 - 11, pp. 2044 - 2049. 2012. ISSN 1531-5037
- 13** Mariam El Assar; Javier Angulo; Susana Vallejo; Concepción Peiró; Carlos F Sánchez Ferrer; Leocadio Rodríguez Mañas. Mechanisms involved in the aging-induced vascular dysfunction. *Frontiers in physiology*. 3, pp. 132. (Switzerland): 2012. ISSN 1664-042X
- 14** Carolina Sánchez Rodríguez; Concepción Peiró; Susana Vallejo; Nuria Matesanz; Mariam El Assar; Verónica Azcutia; Tania Romacho; Carlos Félix Sánchez Ferrer; Leocadio Rodríguez Mañas; Julián Nevado. Pathways responsible for apoptosis resulting from amadori-induced oxidative and nitrosative stress in human mesothelial cells. *American journal of nephrology*. 34 - 2, pp. 104 - 114. (Switzerland): 2011. ISSN 1421-9670
- 15** Susana Vallejo; Tania Romacho; Javier Angulo; Laura A Villalobos; Elena Cercas; Alejandra Leivas; Elena Bermejo; Raffaele Carraro; Carlos F Sánchez Ferrer; Concepción Peiró. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. *PLoS one*. 6 - 11, pp. e27299. 2011. ISSN 1932-6203
- 16** Leocadio Rodríguez Mañas; Mariam El Assar; Susana Vallejo; Pedro López Dóriga; Joaquin Solís; Roberto Petidier; Manuel Montes; Julián Nevado; Marta Castro; Carmen Gómez Guerrero; Concepción Peiró; Carlos F Sánchez Ferrer. Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. *Aging cell*. 8 - 3, pp. 226 - 238. 2009. ISSN 1474-9726
- 17** Nicolás Nin; José A Lorente; Marta de Paula; Mariam El Assar; Susana Vallejo; Oscar Peñuelas; Pilar Fernández Segoviano; Antonio Ferruelo; Alberto Sánchez Ferrer; Andrés Esteban. Rats surviving injurious mechanical ventilation show reversible pulmonary, vascular and inflammatory changes. *Intensive care medicine*. 34 - 5, pp. 948 - 956. 2008. ISSN 0342-4642
- 18** Concepcion Peiró; Susana Vallejo; Florian Gembardt; Verónica Azcutia; Silvia Heringer Walther; Leocadio Rodríguez Mañas; Heinz-Peter Schultheiss; Carlos F Sánchez Ferrer; Thomas Walther. Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. *Journal of hypertension*. 25 - 12, pp. 2421 - 2425. 2007. ISSN 0263-6352
- 19** J Nevado; S Vallejo; M El Assar; C Peiró; C F Sánchez Ferrer; L Rodríguez Mañas. Changes in the human peritoneal mesothelial cells during aging. *Kidney international*. 69 - 2, pp. 313 - 322. 2006. ISSN 0085-2538
- 20** L Rodríguez Mañas; C Sánchez Rodríguez; S Vallejo; M El Assar; C Peiró; V Azcutia; N Matesanz; C F Sánchez Ferrer; J Nevado. Pro-inflammatory effects of early non-enzymatic glycosylated proteins in human mesothelial cells vary with cell donor's age. *British journal of pharmacology*. 149 - 8, pp. 979 - 987. 2006. ISSN 0007-1188



- 21** Julián Nevado; Concepción Peiró; Susana Vallejo; Mariam El Assar; Nuria Lafuente; Nuria Matesanz; Verónica Azcutia; Elena Cercas; Carlos F Sánchez Ferrer; Leocadio Rodríguez Mañas. Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells. *British journal of pharmacology*. 146 - 2, pp. 268 - 279. 2005. ISSN 0007-1188
- 22** L Rodríguez Mañas; J Angulo; S Vallejo; C Peiró; A Sánchez Ferrer; E Cercas; P López Dóriga; C F Sánchez Ferrer. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. *Diabetologia*. 46 - 4, pp. 556 - 566. (Germany): 2003. ISSN 0012-186X
- 23** Concepcion Peiro; Nuria Matesanz; Julian Nevado; Nuria Lafuente; Elena Cercas; Veronica Azcutia; Susana Vallejo; Leocadio Rodriguez Manas; Carlos F Sanchez Ferrer. Glycosylated human oxyhaemoglobin activates nuclear factor-kappaB and activator protein-1 in cultured human aortic smooth muscle. *British journal of pharmacology*. 140 - 4, pp. 681 - 690. 2003. ISSN 0007-1188
- 24** C Peiró; N Lafuente; N Matesanz; E Cercas; J L Llergo; S Vallejo; L Rodríguez Mañas; C F Sánchez Ferrer. High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide. *British journal of pharmacology*. 133 - 7, pp. 967 - 974. 2001. ISSN 0007-1188
- 25** S Vallejo; J Angulo; C Peiró; J Nevado; A Sánchez Ferrer; R Petidier; C F Sánchez Ferrer; L Rodríguez Mañas. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. *Diabetologia*. 43 - 1, pp. 83 - 90. (Germany): 2000. ISSN 0012-186X
- 26** C Peiró; S Vallejo; E Cercas; J L Llergo; N Lafuente; N Matesanz; L Rodríguez Mañas; C F Sánchez Ferrer. Thapsigargin induces apoptosis in cultured human aortic smooth muscle cells. *Journal of cardiovascular pharmacology*. 36 - 5, pp. 676 - 680. 2000. ISSN 0160-2446
- 27** S Vallejo; J Angulo; C Peiró; E Cercas; A Sánchez Ferrer; J Nevado; J L Llergo; L Rodríguez Mañas; C F Sánchez Ferrer. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. *Journal of cardiovascular pharmacology*. 36 - 2, pp. 255 - 262. 2000. ISSN 0160-2446
- 28** J Angulo; L Rodríguez Mañas; C Peiró; S Vallejo; A Sánchez Ferrer; C F Sanchez Ferrer. Impairment of endothelial relaxations by glycosylated human oxyhemoglobin depends on the oxidative state of the heme group. *General pharmacology*. 32 - 4, pp. 475 - 481. 1999. ISSN 0306-3623
- 29** C Peiró; S Vallejo; J Nevado; J Angulo; J L Llergo; E Cercas; L Rodríguez Mañas; C F Sánchez Ferrer. Pharmacological interference of vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. *European journal of pharmacology*. 386 - 2-3, pp. 317 - 321. 1999. ISSN 0014-2999
- 30** C Peiró; J Angulo; L Rodríguez Mañas; J L Llergo; S Vallejo; E Cercas; C F Sánchez Ferrer. Vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. *British journal of pharmacology*. 125 - 4, pp. 637 - 644. 1998. ISSN 0007-1188

### Works submitted to national or international conferences

- 1** **Title of the work:** The Angiotensin-(1-7)/ Mas Receptor Axis Counteract Pro-Inflammatory Signaling in Human Vascular Smooth Muscle Cells  
**Name of the conference:** 37th Congress of the Spanish Society of Pharmacology  
**City of event:** BARCELONA, Spain  
**Date of event:** 2107  
**Organising entity:** SOCIEDAD ESPAÑOLA DE FARMACOLOGIA  
A Romero; L.A Villalobos; A San Hipólito; C Sánchez; M Ramos; E Cercas; S Vallejo; T Romacho; R Carraro; C Peiró.



- 2** **Title of the work:** El eje angiotensina-(1-7)/receptor Mas contrarresta las señales pro-inflamatorias dependientes e independientes de Angiotensina II en células de músculo liso humano  
**Name of the conference:** 22 Reunión Nacional SEH-LELHA  
**City of event:** Madrid, Spain  
**Date of event:** 2017  
**Organising entity:** SEH-LELHA  
L.A VILLALOBOS; A SAN HIPOLITO-LUENGO; M RAMOS-GONZALEZ; E CERCAS; S VALLEJO; A ROMERO; T ROMACHO; R CARRARO; C.F SANCHEZ-FERRER; C PEIRO.
- 3** **Title of the work:** La infusión in vivo de las adipoquinas visfatina e interleucina-1 $\beta$  produce disfunción endotelial en microvasos mesentéricos de ratón  
**Name of the conference:** 22 Reunión Nacional SEH-LELHA  
**City of event:** Madrid, Spain  
**Date of event:** 2017  
**Organising entity:** SEH-LELHA  
M RAMOS GONZALEZ; S VALLEJO; A SAN HIPOLITO; A ROMERO; E CERCAS; C PEIRO; C.F SANCHEZ FERRER.
- 4** **Title of the work:** Efecto de las adipoquinas visfatina/Nampt e interleucina (IL)-1 $\beta$  en el daño vascular de arterias mesentéricas de ratones  
**Name of the conference:** . XXV Reunión de Farmacólogos de la Comunidad de Madrid  
**City of event:** Madrid, Spain  
**Date of event:** 2016  
**Organising entity:** FARMADRID  
S VALLEJO; M RAMOS-GONZALEZ; A SAN HIPOLITO-LUENGO; E CERCAS; C.F SANCHEZ-FERRER; C PEIRO.
- 5** **Title of the work:** Effect of adipokines visfatin and IL (interleukin)-1 $\beta$  in the vascular damage in mice mesenteric microvessels  
**Name of the conference:** 7th European Congress of Pharmacology  
**City of event:** ESTAMBUL, Turkey  
**Date of event:** 2016  
**Organising entity:** EPHAR  
M RAMOS-GONZALEZ; S VALLEJO; A SAN HIPOLITO-LUENGO; E CERCAS; C PEIRO; C.F SANCHEZ-FERRER.
- 6** **Title of the work:** La adipoquina visfatina/Nampt deteriora las relajaciones dependientes de endotelio en arterias mesentéricas tanto in vitro como in vivo  
**Name of the conference:** 21 Reunión Nacional SEH-LELHA  
**City of event:** VALENCIA, Spain  
**Date of event:** 2016  
**Organising entity:** SEH-LELHA  
**Type of entity:** Associations and Groups  
M RAMOS-GONZALEZ; S VALLEJO; A SAN HIPOLITO-LUENGO; E CERCAS; C.F SANCHEZ-FERRER; C PEIRO.
- 7** **Title of the work:** The adipokine Soluble Dipeptidyl Peptidase-4 induces endotelial dysfunction via Proteinase- activated Receptor 2.  
**Name of the conference:** 21th Latin American Congress of Pharmacology  
**City of event:** Foz do Iguazu, Brazil  
**Date of event:** 2016  
**Organising entity:** LATINPHARMA



C PEIRO; T ROMACHO; S VALLEJO; L.A VILLALOBOS; N WRONKOWITZ; I INDRAKUSUMA; H SELL; J ECKEL; C.F SANCHEZ-FERRER.

- 8** **Title of the work:** The adipokine soluble dipeptidyl peptidase-4 impairs microvascular reactivity through proteinase-activated receptor-2 and thromboxane A2 production  
**Name of the conference:** 36th Congress of the Spanish Society of Pharmacology (SEF)  
**City of event:** VALENCIA, Spain  
**Date of event:** 2016  
**Organising entity:** Sociedad Española de Farmacología  
C PEIRO; T ROMACHO; S VALLEJO; L.A Villalobos; N Wronkowitz; I Indrakusuma; H SELL; J Eckel; C.F Sánchez-Ferrer.
- 9** **Title of the work:** Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction by the release of thromboxaneA2  
**Name of the conference:** XXIII Reunión de Farmacólogos de la Comunidad de Madrid  
**City of event:** Madrid, Spain  
**Date of event:** 2014  
**Organising entity:** FARMADRID  
T ROMACHO; S VALLEJO; L.A VILLALOBOS; H WRONKOWITZ; J SELL; C.F ECKEL; C.F SANCHEZ-FERRER.
- 10** **Title of the work:** The activation of the angiotensina (1-7)/Mas receptor axis protects against vascular cell inflammation  
**Name of the conference:** 1st Symposium on Biomedical Research. Advances and perspectives in Cardiovascular Biomedicine.  
**City of event:** Madrid, Spain  
**Date of event:** 2014  
**Organising entity:** Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) - Facultad de Medicina de la UAM  
S VALLEJO; L.A VILLALOBOS; T ROMACHO; E CERCAS; M.J SANZ; C PEIRO; C.F SANCHEZ-FERRER.
- 11** **Title of the work:** Inflammation enhances visfatin synthesis in the vascular wall  
**Name of the conference:** Symposium der Deutschen Gessellschaft fur Endokrinologie  
**Date of event:** 2013  
C.F SANCHEZ-FERRER; T ROMACHO; L.A VILLALOBOS; S VALLEJO; E CERCAS; R CARRARO; C PEIRO.
- 12** **Title of the work:** El eje ANGIOTENSINA-(1-7)/MAS exhibe propiedades antiinflamatorias en células vasculares humanas de músculo liso  
**Name of the conference:** 5ª Reunión de Investigación en Fisiopatología Vasculard de la SEH-LELHA Reunión Nacional SEH-LELHA.  
**City of event:** Madrid, Spain  
**Date of event:** 2012  
**Organising entity:** SEH-LELHA  
L VILLALOBOS; T ROMACHO; E CERCAS; C.F SANCHEZ-FERRER; C PEIRO; S VALLEJO.
- 13** **Title of the work:** Mechanisms involved in the age-related vascular endothelial dysfunction  
**Name of the conference:** Vascular inflammation, aging and Imaging  
**City of event:** Madrid, Spain  
**Date of event:** 2012  
**Organising entity:** CNIC CONFERENCE



C.F. SANCHEZ-FERRER; L RODRIGUEZ-MAÑAS; J ANGULO; S VALLEJO; M EL-ASSAR; C GOMEZ-GUERRERO; P LOPEZ-DORIGA; E PALACIOS; J NEVADO; C PEIRO.

- 14** **Title of the work:** The adipocytokine visfatin as a promoter of vascular inflammation and endothelial dysfunction  
**Name of the conference:** Vascular inflammation, aging and Imaging  
**City of event:** Madrid, Spain  
**Date of event:** 2012  
**Organising entity:** CNIC CONFERENCE **Type of entity:** Public Research Body  
T ROMACHO; L.A VILLALOBOS; S VALLEJO; E CERCAS; J ANGULO; R CARRARO; C.F SANCHEZ-FERRER; C PEIRO.
- 15** **Title of the work:** Characterization of endothelium-dependent relaxations in children mesenteric vasculature: potential pathophysiological relevance  
**Name of the conference:** 24th International Symposium on Pediatric Surgical Research  
**City of event:** GRAZ, Austria  
**Date of event:** 2011  
**Organising entity:** Association for the Pediatric Surgical Research  
f RIVILLA; S VALLEJO; A.J HOBBS; C PEIRO; C.F SANCHEZ-FERRER.
- 16** **Title of the work:** The Angiotensina (1-7)/MASaxis exhibits anti-inflammatory properties in vascular human smooth muscle cells.  
**Name of the conference:** XXXIII Conference of the Spanish Society of Pharmacology.  
**City of event:** MALAGA, Spain  
**Date of event:** 2011  
**Organising entity:** Spanish Society of Pharmacology  
L VILLALOBOS; T ROMACHO; E CERCAS; C.F SANCHEZ FERRER; C PEIRO; S VALLEJO; S VALLEJO.
- 17** **Title of the work:** The adipocytokine VISFATIN/PBEF/Nampt is synthesized in the vascular wall in response to proinflammatory stimuli.  
**Name of the conference:** 16th Annual Meeting of the European Council for Cardiovascular Research  
**City of event:** NIZA, France  
**Date of event:** 2011  
**Organising entity:** European Council for Cardiovascular Research (ECCR)  
T ROMACHO; S VALLEJO; L VILLALOBOS; E CERCAS; A LEIVAS; R CARRARO; C.F SANCHEZ-FERRER; C PEIRO.
- 18** **Title of the work:** The adipocytokine/PBEF/Nampt is synthesized in the vascular wall in response to proinflammatory stimuli  
**Name of the conference:** 18th European Congress on Obesity (ECCO 2011)  
**City of event:** ESTAMBUL, Turkey  
**Date of event:** 2011  
**Organising entity:** European Association for the Study of Obesity  
T ROMACHO; E CERCAS; S VALLEJO; L VILLALOBOS; R CARRARO; C.F. SANCHEZ-FERRER; C PEIRO.
- 19** **Title of the work:** The adipocytokine/PBEF/Nampt induces endothelial dysfunction and promotes vascular cell inflammation  
**Name of the conference:** 18th European Congress on Obesity (ECCO 2011)  
**City of event:** ESTAMBUL, Turkey  
**Date of event:** 2011  
**Organising entity:** European Association for the Study of Obesity





C PEIRO; T ROMACHO; L VILLALOBOS; E CERCAS; S VALLEJO; R CARRARO; C.F SANCHEZ-FERRER.

- 20 Title of the work:** Disfunción endotelial causada por el aumento extracelular de D-glucosa e interleuquina-1 $\alpha$ .  
**Name of the conference:** XIX Reunión de Farmacólogos de la Comunidad de Madrid  
**City of event:** Madrid, Community of Madrid, Spain  
**Date of event:** 2010  
**Organising entity:** FARMADRID  
E. PALACIOS; S. VALLEJO; E. CERCAS; C. PEIRO; C.F. SANCHEZ-FERRER.
- 21 Title of the work:** La adipoquina PBEF/NAMPT/visfatina induce disfunción endotelial en arterias de resistencia de rata  
**Name of the conference:** XIX Reunión de Farmacólogos de la Comunidad de Madrid  
**City of event:** Madrid, Community of Madrid, Spain  
**Date of event:** 2010  
**Organising entity:** FARMADRID  
S VALLEJO; T ROMACHO; R. CARRARO; J. ANGULO; A. FERNANDEZ; C PEIRO; C.F. SANCHEZ-FERRER.
- 22 Title of the work:** The adipokine PBEF/Nampt/visfatin induces endothelial dysfunction in rat resistance arteries  
**Name of the conference:** 32 Congreso de la Sociedad Española de Farmacología  
**City of event:** LEON, Spain  
**Date of event:** 2010  
**Organising entity:** Sociedad Española de Farmacología  
**City organizing entity:** Sociedad Española de Farmacología, Spain  
S VALLEJO; T ROMACHO; R CARRARO; J ANGULO; A FERNANDEZ; C PEIRO; C.F. SANCHEZ-FERRER. "European Journal of Clinical Pharmacology 66: S67, 2010".
- 23 Title of the work:** Visfatina/NAMPT/PBEF: una nueva diana farmacológica en inflamación vascular  
**Name of the conference:** XIX Reunión de Farmacólogos de la Comunidad de Madrid  
**City of event:** Madrid, Spain  
**Date of event:** 2010  
**Organising entity:** FARMADRID  
T ROMACHO; E. CERCAS; S. VALLEJO; R. CARRARO; L. VILLALOBOS; C.F. SANCHEZ-FERRE; C. PEIRO.
- 24 Title of the work:** Disfunción endotelial inducida por la inhibición farmacológica o delección genética del receptor Mas.  
**Name of the conference:** 14ª Reunión nacional Sociedad Española de Hipertensión Liga Española para la Lucha contra la Hipertensión arterial (SEH-LELHA).  
**City of event:** MALAGA, Spain  
**Date of event:** 2009  
**Organising entity:** Sociedad Española de Hipertensión  
M. VAZQUEZ-BELLA; V. AZCUTIA; T ROMACHO; S. VALLEJO; L. RODRIGUEZ-MAÑAS; C. HERMENEGILDO; T WALTHER; C. PEIRO; C.F. SANCHEZ-FERRER. "Hipertensión. 26:6-7, 2009".
- 25 Title of the work:** The role of the angiotensin-(1-7) receptor Mas ais in endothelial dysfunction  
**Name of the conference:** 31 Congreso de la Sociedad Española de Farmacología  
**City of event:** SEVILLA, Spain  
**Date of event:** 2009



**Organising entity:** Sociedad Española de Farmacología

M. VAZQUEZ-BELLA; S VALLEJO; V. AZCUTIA; E. CERCAS; E. PALACIOS; L. RODRIGUEZ-MAÑAS; S. NOVELLA; C. HERMENEGILDO; T. WALTHER; C. PEIRO; C.F. SANCHEZ-FERRER. "Methods and Findings in Experimental and Clinical Pharmacology 31 suppl A: 140, 2009."

**26 Title of the work:** Role of diabetes mellitus and hypertension on age-related human endothelial dysfunction

**Name of the conference:** 30 Congreso de la Sociedad Española de Farmacología

**City of event:** BILBAO, Spain

**Date of event:** 2008

**Organising entity:** Sociedad Española de Farmacología

S. VALLEJO; M. EL ASSAR; M. VAZQUEZ; M. CASTRO; C. SANCHEZ-RODRIGUEZ; C. PEIRO; C.F. SANCHEZ-FERRER; L. RODRIGUEZ-MAÑAS. "Methods and Findings in Experimental and Clinical Pharmacology 30 suppl 2: 116, 2008."